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Abstract
Background: Intramuscular pethidine is routinely used throughout the UK for labour analgesia. Studies have
suggested that pethidine provides little pain relief in labour and has a number of side effects affecting mother and
neonate. It can cause nausea, vomiting and dysphoria in mothers and can cause reduced fetal heart rate variability
and accelerations. Neonatal effects include respiratory depression and impaired feeding. There are few large studies
comparing the relative side effects and efficacy of different opioids in labour. A small trial comparing intramuscular
pethidine with diamorphine, showed diamorphine to have some benefits over pethidine when used for labour
analgesia but the study did not investigate the adverse effects of either opioid.
Methods: The Intramuscular Diamorphine versus Intramuscular Pethidine (IDvIP) trial is a randomised double-blind
two centre controlled trial comparing intramuscular diamorphine and pethidine regarding their analgesic efficacy in
labour and their side effects in mother, fetus and neonate. Information about the trial will be provided to women in
the antenatal period or in early labour. Consent and recruitment to the trial will be obtained when the mother
requests opioid analgesia. The sample size requirement is 406 women with data on primary outcomes. The maternal
primary outcomes are pain relief during the first 3 hours after trial analgesia and specifically pain relief after 60
minutes. The neonatal primary outcomes are need for resuscitation and Apgar Score <7 at 1 minute. The secondary
outcomes are an additional measure of pain relief, maternal sedation, nausea and vomiting, maternal oxygen
saturation, satisfaction with analgesia, whether method of analgesia would be used again, use of Entonox, umbilical
arterial and venous pH, fetal heart rate, meconium staining, time from delivery to first breath, Apgar scores at 5 mins,
naloxone requirement, transfer to neonatal intensive care unit, neonatal haemoglobin oxygen saturation at 30, 60, 90,
and 120 mins after delivery, and neonatal sedation and feeding behaviour during first 2 hours.
Discussion: If the trial demonstrates that diamorphine provides better analgesia with fewer side effects in mother
and neonate this could lead to a change in national practice and result in diamorphine becoming the preferred
intramuscular opioid for analgesia in labour.
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Background
Labour is generally considered to be a painful experience
and analgesia is regularly required. Intramuscular opioids
are one form of analgesia regularly employed. Intramus-
cular pethidine is routinely used throughout the UK for
labour analgesia and is the only opioid licensed for inde-
pendent use by midwives. There are a number of con-
cerns in the literature regarding the use of pethidine.
Some studies have suggested that pethidine provides little
or no pain relief in labour, its main effect being to cause
sedation rather than analgesia [1,2]. Pethidine also has a
number of side effects on both the mother and the neo-
nate which make it a less than ideal choice for labour
analgesia. It can cause nausea, vomiting and dysphoria in
women receiving it during labour [3]. It also crosses the
placenta and can cause reduced fetal heart rate variability
and fewer heart rate accelerations [4]. Effects on the neo-
nate include respiratory depression, impaired feeding and
altered crying [5-7].
Despite the disadvantages of pethidine, there are few
large studies comparing the relative side effects and
effectiveness of different opioids in labour and systema-
tic reviews comparing parenteral opioids in labour have
suggested a need for well-designed and suitably-sized
trials of pethidine versus other opioids [8,9]. A small
trial comparing intramuscular pethidine with diamor-
phine, showed diamorphine to have some benefits over
pethidine when used for labour analgesia but the trial
did not study the potential adverse effects of either
opioid [10]. A national survey published in 2008 relating
to use of intramuscular opioids for analgesia in labour
in consultant-led units in the UK revealed that diamor-
phine was used in 34% of maternity units and was the
most commonly used opioid for analgesia in labour in
Scotland [11]. Where it is used, anecdotally it is per-
ceived to provide superior analgesia with fewer side
effects than pethidine, but to date there is no published
large randomised controlled trial to support this impres-
sion. We aim to undertake a two-centre double-blind
randomised controlled trial comparing intramuscular
diamorphine and pethidine in terms of their analgesic
efficacy in labour and their side effects in mother, fetus
and neonate.
Methods/design
This two-centre double-blind randomised controlled
trial comparing intramuscular diamorphine and pethi-
dine will be conducted at Poole Hospital NHS Founda-
tion Trust (PHFT), the Sponsor site, and the Royal
United Hospital, Bath (RUH). Southampton and South
West Hampshire Ethics Committee granted ethical
approval. Information about the trial will be provided to
women and consent obtained in the antenatal period via
the antenatal clinics, both in the community and mater-
nity hospital, or in early labour in the delivery suite
prior to the request for analgesia. Consented women
will be recruited to the trial when there is maternal
request in labour for opioid analgesia.
Inclusion criteria
The women recruited will be those who have given writ-
ten informed consent, who are in active labour with a
singleton pregnancy, defined as regular uterine contrac-
tions of at least 2 in 10 minutes and cervical dilatation
of at least 3 cms, with fetal gestational age of 37-42
weeks and a minimum weight of 60 kg. Competent
women of sixteen years old or older are eligible. Both
multiparous and nulliparous women will be eligible
including those who have either gone into labour spon-
taneously or who have had an amniotomy and intrave-
nous oxytocin to induce labour.
Exclusion criteria
Exclusion criteria include lack of informed consent,
allergy or previous severe reaction to opioid analgesia,
opioid dependency, use of parenteral opioids within the
previous 24 hours, history of fetal compromise, maternal
cardiorespiratory compromise, ASA 3 & 4 (severe sys-
temic disease including threat to life), maternal weight
greater than 120 kgs or less than 60 kg.
Allocation of analgesia
Once recruited, women will be randomly allocated to
receive either intramuscular pethidine 150 mg or diamor-
phine 7.5 mg into the gluteus muscle or muscles of the
lateral thigh. Qualassept Ltd is supplying the pre-filled
syringes of pethidine and diamorphine to the respective
pharmacies in Poole Hospital NHS Foundation Trust or
the Royal United Hospitals Bath NHS Trust. The study
drug will be dispensed in batches of two syringes by
pharmacy. The syringes will be labelled only with a trial
number in order to conceal group allocation from both
the midwife and the parturient, and to ensure that if two
doses are given, the same opioid is given both times. Ran-
domisation will use random block sizes between 2 and 10
to ensure approximately equal group sizes, be stratified
by centre and generated using PEPI [12]. The method is
administered by the pharmacies and ensures parturients,
researchers, maternity unit staff and trial statistician are
blind to allocation. Parturients will also receive Metoclo-
pramide 10 mg with the first dose, in line with current
department prescribing guidelines. A maximum of two
doses of opioid may be given with a minimum interval of
2 hours if the women requests additional analgesia.
Regional analgesia or Entonox will be available as rescue
analgesia.
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Measurements
• General demographics. Age, weight, gestational age,
cervical dilatation at first request for analgesia, fre-
quency of contractions, parity, spontaneous or
induced labour, use of syntocinon, presentation,
mode of delivery, drug administration to delivery
interval. This information will be derived from the
maternal notes and interview with the midwife tak-
ing care of the parturient.
• Maternal Pain Evaluation. Pain severity during last
contraction will be assessed using a visual analogue
score (VAS) (with anchor points of 0 = no pain at
all and 10 = the most excruciating pain) and verbal
scales of pain intensity during the last contraction
(pain intensity score: 0 = no pain; 1 = mild pain; 2 =
moderate pain; 3 = severe pain). In addition, the
midwife will assess pain relief during the previous 30
minutes (pain relief score: 0 = none; 1 = slight; 2 =
moderate; 3 = good, 4 = complete).
• Maternal Sedation and Vomiting Evaluation.
Maternal sedation during the previous 30 minutes
will be assessed by the midwife using sedation scores
(0 = alert; 1 = mild i.e. occasionally drowsy and
easily aroused; 2 = moderate sedation i.e. frequently
drowsy but still easily aroused; 3 = severe sedation
i.e. somnolent and difficult to rouse) and by measur-
ing maternal oxygen saturation by pulse oximetry.
Maternal pulse oximetry measurement is integral
within the cardiotocograph (CTG) machine (Phillips
PN/2703A) at the RUH and using the Masimo Rad
5 machine at PHFT. Vomiting will be assessed as a
side effect with a yes/no answer pre-dose and during
each subsequent thirty minutes period.
Maternal assessments will be made when the woman
first requests analgesia and then every thirty minutes
after the trial drug has been given, for a maximum of
three hours or until delivery has occurred or additional
analgesia is requested. A further 3 hours of measure-
ments are then made if additional opioid analgesia is
requested not less than 2 hours after the first dose. The
parturient’s overall satisfaction with the analgesia will
also be assessed 12-24 hours post partum as well as
their wish to choose the same opioid for their next
labour analgesia.
• Fetal Monitoring. Fetal well-being will be monitored
by continuous monitoring of fetal heart rate baseline
and variability according to standard department pro-
tocols and classified as Reassuring (baseline 110-160
bpm, variability >5 bpm, no decelerations and accel-
erations present); Non-reassuring (baseline 100-109
or 161-180, variability of <5 for >40 but <90 minutes,
and early or variable decelerations or a single pro-
longed deceleration up to 3 minutes) or Abnormal
(Baseline <100 or >180 or sinusoidal pattern for >10
minutes, variability of <5 for >90 minutes, and atypi-
cal variable decelerations or late decelerations or a
single prolonged deceleration of greater than 3 min-
utes). CTG monitoring is made using Corometrics
170 series machine in PHFT and using the Phillips
PN/2703A machine at RUH. If meconium staining
occurs then the time of first appearance in relation to
administration of trial drug will be noted. At delivery
cord blood will be taken for measurement of umbili-
cal arterial and venous pH.
• Neonatal Monitoring. Neonatal condition will be
assessed by time to first breath, Apgar score at 1 min-
ute and 5 minutes, need for naloxone, need for resus-
citation by bag mask ventilation or intubation and
transfer to Neonatal Intensive Care Unit (NICU).
Neonatal oxygen saturation will also be measured
every 30 minutes from birth for 2 hours using the
Masimo Rad 5 pulse oximeter at PHFT and Mindray
PM-60 at RUH. Neonatal sedation in the first 2 hours
of life will also be recorded using the same scoring
system as the parturient. Time from delivery to first
feed will be recorded as well as a subjective assess-
ment of feeding behaviour by the midwife (0 = nor-
mal; 1 = mildly depressed rooting and sucking
behaviour; 2 = severely depressed rooting and sucking
behaviour) during the first 2 hours of life.
Primary outcome measures
Maternal
Pain relief Measured using change in pain intensity
from pre-analgesia levels over the subsequent 3 hours.
Pain relief at 60 minutes Measured by change from
baseline in pain intensity VAS at 60 minutes. The dose
of analgesia is administered intra-muscularly, and it is
anticipated that maximum analgesic effect will occur at
around 60 minutes after administration. Pain intensity
at 60 minutes was the primary outcome used by Fairlie
et al [10], and is the basis of our sample size calculation.
Neonatal
Side effects (a) Need for neonatal resuscitation
(b) Apgar Score <7 at 1 minute
Secondary outcome measures
Maternal
Pain (a) Verbal pain intensity over first 3 hours
(b) Verbal pain intensity at 60 minutes post
administration
(c) Pain relief score over first 3 hours
(d) Maternal satisfaction with analgesia 12-24 hours
after delivery
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Other (e) Maternal sedation score over first 3 hours
(f) Time from first dose to delivery
(g) Entonox or regional analgesia given
(h) Nausea over 3 hours
(i) Vomiting over 3 hours
(j) Oxygen saturation over 3 hours after each dose of
study drug or until delivery
(j) Percent reporting that they would choose the same
pain relief in their next pregnancy
Neonatal
(a) Cardiotocography over the first 3 hours after each
dose of study drug or until delivery
(b) Time from first dose to first meconium staining
(c) Umbilical artery pH and vein pH
(d) Time from delivery to first breath
(e) Apgar score at 5 mins
(f) Requirement for naloxone
(g) Neonatal oxygen saturation at 30 mins, 60 mins,
90 mins, 120 mins after delivery
(h) Time from delivery to first feed
(i) Feeding behaviour during first 2 hours
(j) Neonatal sedation in the first 2 hours after delivery
(k) Transfer to neonatal intensive care unit
Sample Size
The number of women to be recruited has been deter-
mined using a sample size calculation, and is based upon
the maternal primary outcome measure of pain relief at 60
minutes, and the neonatal primary outcome measures of
Apgar score < 7 at 1 minute and neonatal resuscitation.
We could find no data on our specific maternal primary
outcome on which to base the sample size calculation (i.e.
change in pain intensity). However, Fairlie et al in their
randomised trial of pethidine versus diamorphine [10]
reported on VAS pain intensity at 60 mins post adminis-
tration of the first dose, and we have based our sample
size calculation upon this. A standard deviation (SD) for
pain intensity post opiate administration can be estimated
from the data they present (SD = 2.6), and we have esti-
mated the SD of change in pain intensity using 3 scenarios
of different correlations between post-analgesia and pre-
analgesia scores; correlations of 0.3, 0.5 and 0.7 give SDs
of 3.1, 2.6 and 2.0 respectively. A 1 cm difference on a
10 cm VAS represents 10% of the scale, and to detect
mean differences of this magnitude between the two arms
of the trial with 90% power (at the 5% significance level)
will require sample sizes of 203, 144 and 86 per group
respectively in the 3 scenarios. A 1 cm difference is similar
to the difference in pain intensity at 60 minutes found by
Fairlie (0.9), is not larger than the 1.4 cm identified by
Holdgate et al [13] as being the minimum change in pain
that can be subjectively identified by patients with acute
pain, and represents a standardised effect size of 0.38. We
will set sample size at the higher figure of 203 per group.
Regarding neonatal outcomes, the Fairlie trial found
that around 30% of neonates required resuscitation, and
that around 25% of neonates whose mothers were given
pethidine had 1 minute Apgar scores of less than 7 [10].
Thus with 203 participants per group the study will
have 90% power to detect reductions of around 50% in
both these outcomes (i.e 30% v 16% and 25% v 12%
respectively). The difference for Apgar scores is similar
to that found by Fairlie et al [10].
Initially we will aim to recruit 450 to allow for the fact
that not all women will have data on pain intensity, for
example if they delivered soon after administration of
the trial drug. However we will monitor this during the
trial and alter our recruitment target accordingly.
The recruitment target will be split evenly between the 2
trial sites. In Poole there are approximately 4000 deliveries
per year and at Royal United Hospital Bath there are
approximately 3,500 (based on 2008 figures). Assuming a
low recruitment rate of 10%, and taking into account that
pethidine is currently administered to approximately 40%
of women, recruitment should take around 24 months.
Statistical Analysis
Women will be analysed in the group to which they were
originally randomised, regardless of what subsequently
occurred during their labour. To enable this, where
appropriate, all measures will be collected on all women
once they have been randomised. However, within this
framework, women could still, at any time, withdraw
their consent to be in the trial.
Data will be analysed using SPSS for Windows and
MLWin [14]. Significance tests will use a 5% two-sided
significance level. Randomisation will be stratified by study
site, and this will be controlled for in all analyses. Given
the design of the trial, it is anticipated that missing data
will be mostly negligible. The exception will be for the
observations taken at 30 minute intervals after administra-
tion of the trial drug, where observations will cease if the
mother delivers. We will assume these missing data are
“missing at random” [15]. Analysis of the two maternal
primary outcome measures will be as follows. Pain relief
will be measured at 30 minute intervals over 3 hours. The
repeated measures nature of the data will be taken into
account using a maximum likelihood based multi-level
(mixed) model [14]. This model permits analysis of unba-
lanced repeated measures data thus avoiding exclusion of
participants with incomplete data [14]. Initially the inter-
action between trial group and timing of pain VAS mea-
surement will be tested to see if the effects of the study
drug change over time. If the interaction effect is not sta-
tistically significant, the interaction will be removed from
the multi-level model and the main effect of trial group
tested. Parameter estimates with 95% confidence intervals
will be presented. The second maternal primary outcome
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measure, mean difference in pain relief at 60 minutes, will
be estimated using multiple regression.
The neonatal primary outcomes, need for resuscitation
and Apgar score under 7 at 1 minute, will be compared
between groups using logistic regression, and the results
presented as odds ratios (95% CI) and Numbers Needed
to Treat (NNT).
Supplementary analyses will adjust for the following
covariates that might have an impact on primary out-
comes: maternal age, parity, gestation, pre-administra-
tion pain intensity. No formal correction for multiplicity
will be applied to the significance tests for the 4 pri-
mary outcomes. Under the null hypothesis that the two
treatment groups give identical outcomes, the probabli-
ties of 1 or more, 2 or more, 3 or more, or all 4 being
statistcally significant are 0.19, 0.01,<0.001 and <0.001
respectively. The trial report will include a section on
the impact of multiplicity on interpretation of the
results.
Analysis of secondary outcome measures is likely to be
as follows. The distributions of oxygen saturation and
nausea VAS are likely to be highly skewed and so values
will be categorised. For example, as under 95, 95-97, 98-
100 for oxygen saturation and 0, 0.1-4.9, 5+ for nausea.
These and other repeated measures categorical outcomes
(verbal pain intensity, pain relief, maternal sedation,
vomiting, cardiotocography) will be analysed in two ways;
(a) using repeated measures models, and (b) as the pro-
portion of women having a poor result during the 3 hour
follow-up, using logistic regression (eg proportions hav-
ing oxygen saturation 97 or below, nausea 5+, verbal pain
intensity moderate or worse, pain relief none or slight,
sedation moderate or severe, vomiting, cardiotocography
non-reassuring or abnormal). Neonatal oxygen saturation
and sedation scores in the 2 hours after delivery will be
analysed using a similar approach.
Maternal satisfaction with analgesia and neonatal feed-
ing behaviour (normal, mildly depressed, severely
depressed) will be analysed using multinomial logistic
regression.
Dichotomous outcomes such as Apgar score < 7 at 5
minutes, use of naloxone, transfer to neonatal intensive
care unit, and reporting that they would choose the same
analgesia for their next pregancy, will be analysed using
logistic regression.
Time from first administration of study drug to deliv-
ery, and time to first meconium staining (excluding
those where staining ocurred prior to trial drug), and
time from delivery to first feed and time to first breath
will be analysed using proportional hazards models, and
the results presented as hazard ratios.
Multiple regression will be used to analyse umbilical
artery pH and vein pH. Results will be presented with
95% confidence intervals whenever possible.
Both trial drugs are widely used in the NHS and inter-
nationally. No interim analysis is planned, but will be
conducted if specifically requested by the trial Data and
Safety Monitoring Committee. The main role of the
DSMC will be to monitor serious adverse events.
Results will be reported using CONSORT guidelines
[16].
Retention of Data Records and Data Protection
Data records will be kept in a secure locked cupboard
for a period of 30 years. All data will be held on RUH
and PHFT computers, which are password protected.
The data on computers will be anonymised and comply
with the Data Protection Act.
Adverse Event Reporting
Definitions
An Adverse Event (AE) is defined as any untoward
medical occurrence or experience in a patient or clini-
cal investigation subject which occurs following the
administration of the trial medication regardless of the
dose or causal relationship. This can include any unfa-
vourable and unintended signs or symptoms, an
abnormal laboratory finding or a disease temporarily
associated with the use of the protocol treatment
whether or not related to the medicinal product. For
example:
• any new diagnosis
• any symptom that requires medicinal clarification
or leads to in-patient admission
• any suspected adverse drug reaction
• any symptom that appears on the participant’s
medical records
• any event related in time with the intake of the
study medication and affecting the health of the par-
ticipant (including laboratory value changes)
Adverse Event Severity (AEs)
All AEs will be examined to determine severity. The
intensity of an AE, as assessed by the investigator, will
be recorded as either ‘mild’, ‘moderate’ or ‘severe’, as
indicated by the following definitions:
• Mild: an event that requires minimal clinical treat-
ment, or an AE requiring monitoring but no inter-
vention or treatment; causes slight discomfort
• Moderate: an event that requires non-routine
intervention; i.e. a new clinical treatment or diagnos-
tic procedure, administered within an hour of the
event; causes annoying discomfort.
• Severe: incapacitating with inability to do usual
activities or significantly affects clinical status, and
warrants intervention.
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Relationship of the Adverse Event to Study Treatment
An AE is considered associated with the use of the
drug if the attribution is classified as “Possible”,
“Probable” or “Very Likely”.
Causality definitions
Unrelated: There is sufficient information available
to show that the aetiology is unrelated to the drug.
Unlikely: An AE for which an alternative explana-
tion is more likely (e.g. concomitant medications,
concomitant diseases), and/or the relation with time
suggests that a causal relationship is unlikely.
Possible: An AE which might be due to the use of
the drug. An alternative explanation (e.g. concomi-
tant medications, concomitant diseases) is inconclu-
sive. The relationship in time is reasonable; therefore
the causal relationship cannot be excluded.
Probable: An AE which might be due to the use of
the drug. The relationship in time is suggestive. An
alternative explanation is less likely (e.g. concomitant
medications, concomitant diseases).
Very likely: An AE, which is listed as a possible
adverse reaction and cannot be reasonably, explained
by an alternative explanation (e.g. concomitant med-
ications, concomitant diseases). The relationship in
time is very suggestive.
Adverse Drug Reactions (ARs) are responses to a
drug which are noxious and unintended and which
occur at doses normally used in man for prophylaxis,
diagnosis, or therapy of diseases or for modification of
physiological function. An adverse ‘reaction’, contrary to
an ‘event’ is characterised by the fact that a causal rela-
tionship between the drug and the occurrence is sus-
pected, i.e. judged possible by the reporting or a
reviewing health professional.
An Unexpected Adverse Drug Reaction is any
adverse reaction for which the nature or severity is not
consistent with the applicable product information.
A Serious Adverse Event (SAE) is defined as any unde-
sirable experience occurring to the patient, whether or not
considered related to the protocol treatment. A SAE
which is considered related to the protocol treatment is
defined as a Serious Adverse Drug Reaction (SADR).
A Suspected Unexpected Serious Adverse Reaction
(SUSAR) is classified as ‘unexpected’ i.e. a serious
adverse reaction, the nature and severity of which is not
consistent with the information about the medicinal
product in question set out in the summary of product
characteristics for the product.
Adverse events and adverse drug reactions which are
considered as serious are those which result in death; a
life threatening event; prolongation of hospitalisation;
persistent or significant disability/incapacity, a congenital
anomaly/birth defect; any other medically important
condition (i.e. important adverse reactions that are not
immediately life threatening or do not result in death or
hospitalisation but may jeopardise the patient or may
require intervention to prevent any of the other out-
comes listed above).
Reporting Procedure
The documentation of reporting of SAEs should be in
accordance with ICH guidelines for Good Clinical Prac-
tice (5.17.1, 5.17.2 and 5.17.3) [17].
All serious adverse events (SAEs) or drug reactions
(SDRs) (e.g. allergic reaction) arising from the use of the
diamorphine or pethidine occurring from time of rando-
misation until 30 days after the last protocol treatment
administration, will be reported to the following bodies:-
a) MHRA
b) Southampton and South West Hampshire
Research Ethics Committee
c) Sponsor (Poole Hospital NHS Foundation Trust)
via the local Trust adverse incident reporting form
(AIRS form) and also to the Research Governance
Departments of the respective Trusts.
d) Chair of the Data and Safety Monitoring
Committee
Reporting will be done by fax within 24 hours of
the initial observation of the event. The principal
investigator will decide if these events are related
to the protocol treatment or not. Completed doc-
umentation of any reported adverse events or ser-
ious adverse drug reactions will be returned
within 10 days of the initial report by the principal
investigator. SAE will be followed until significant
changes return to baseline, the event stabilises or
is no longer considered as clinically significant by
the investigator, or patient dies or withdraws
consent.
Documentation of adverse events
Patients will be monitored for the duration of the
study and any AEs occurring will be documented in
their research files (CRFs).
The following information will be documented for
each AE:
• nature of the event
• date and time of onset
• interval between the first administration of the
study drug and the onset of the AE
• concomitant treatment; product, indication,
dosage, dosage interval, presentation, mode of
administration and administration regimen
• duration of the AE
• frequency
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• severity (mild/moderate/severe)
• seriousness assessed according to the definition of
an SAE as previously described
• causality assessed according to the causality defini-
tion previously described
• actions taken at the onset of AEs such as no mea-
sures, AE/symptom was treated medically, or other
measures (specified)
• outcome, classified as resolved, unresolved, resol-
ving, resolved with sequelae, death or unknown
• whether the event led to withdrawal from the
study
Steering Group
The Steering Group will comprise of the chief and prin-
cipal investigators and co-applicants (anaesthetists, mid-
wives, obstetrician, statistician) and will also consist of
lay representative, a representative from the National
Childbirth Trust, the Research Governance Manager
and the Sponsor. The Steering Group will meet at least
three times per year during the trial to discuss the con-
duct of the trial, recruitment targets, adverse events and
any concerns arising from the trial.
Data and Safety Monitoring Committee (DSMC)
The DSMC will consist of an independent chair, Prof.
Philip Steer, Emeritus professor of Obstetrics, Imperial
College, London; lay members, consultant anaesthetists,
neonatologist and statistician with ethics experience all
independent from the Steering Group. The chief investi-
gator will provide the DSMC with minutes of the Steer-
ing Group meetings, anonymised details of all the
adverse events and any other data requested by the
chair of the DSMC.
Discussion
This will be the first RCT with adequate power to com-
pare the analgesic and side effect profiles of intramuscu-
lar diamorphine and pethidine for analgesia in labour. If
diamorphine is demonstrated to be the superior drug in
terms of efficacy and side effects, this could lead to a
change in national practice in the United Kingdom to
the benefit of mother, fetus and neonate based on good
evidence. Pethidine is also widely used worldwide and
this study has the potential to alter its worldwide usage.
Intellectual Property Rights
We do not envisage any intellectual property rights issues.
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